FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated May 1, 2018
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 1, 2018
|
GENETIC TECHNOLOGIES LIMITED | ||
|
| ||
|
| ||
|
By: |
/s/ Kevin Fischer | |
|
|
Name: |
Kevin Fischer |
|
|
Title: |
Company Secretary |
ASX ANNOUNCEMENT
1 May 2018
NHMRC Partnership Grant awarded to University of Melbourne
Collaborators Aims to Substantially Improve Breast Cancer Risk Prediction
and Increase Accessibility
Melbourne, Australia, 1 May 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, Company), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC Partnership Grant to a research team led by Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health at The University of Melbourne.
Genetic Technologies Scientific Director, Dr Richard Allman is a co-investigator on this award which aims to substantially improve breast cancer risk prediction, but importantly, also aims to improve patient accessibility to such a test. There is growing acceptance of SNP-based risk assessment both within the medical and scientific communities. One of the key commercial barriers is clinical validity and this research program will expand the current knowledge base to inform strategies for wider-scale community adoption. As the sole commercial partner, a major benefit is that the Company, under this collaboration will have the right of first refusal to commercialise any new scientific discoveries.
Professor John Hopper, Director (Research) of the Centre for Epidemiology and Biostatistics stated that; This prestigious grant award provides us with significant impetus to translate our scientific work into the clinical arena. We have identified potential improvements to current risk assessment paradigms, which if proven have the potential to improve breast cancer screening and prevention programs substantially.
Genetic Technologies Scientific Director, Dr Richard Allman commented; I am extremely pleased to be associated with Professor Hoppers team as a co-investigator on this award. The project team has the necessary expertise to complete the proof-of-concept research, implement the new technology in the commercial arena and generate the ancillary research needed to confirm the expected clinical utility of the new predictive models.
FOR FURTHER INFORMATION PLEASE CONTACT
Dr Paul Kasian |
Jason Wong (USA)) |
Director & Interim CEO |
Blueprint Life Science Group |
Genetic Technologies Limited |
+1 (415) 375 3340, Ext. 4 |
+ 61 3 8412 7000 |
|
Genetic Technologies Limited · Website: www.gtglabs.com · Email: info@gtglabs.com ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 · Fax +61 3 8412 7040
About The University of Melbourne
Founded in 1853, The University of Melbourne is an internationally recognised, research-intensive university with a strong tradition of excellence in teaching, research and community engagement spanning more than 160 years.
Its outstanding performance in international rankings puts The University of Melbourne at the forefront of higher education globally. It is ranked number 1 in Australia by the Times Higher Education World University Rankings and 32nd worldwide. Melbournes position as Australias top University has also been reaffirmed in the 2017 Shanghai Jiao Tong rankings, in which it has moved up to 39th in the World.
The University is uniquely located on the fringe of the city of Melbournes central business district. It serves as a hub for the Parkville research precinct one of the worlds leading centres of medical and biotechnological research.
About 50,000 of the best and brightest students from around the globe come to study at the University of Melbourne.
About Genetic Technologies Limited
Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.